International HapMap Project

International HapMap Project. The International HapMap Project was a groundbreaking genomics project that aimed to create a public database of common genetic variation in the human genome, led by David Altshuler and Francis Collins. This project was a collaboration between National Institutes of Health (NIH), Wellcome Trust, and Genome Canada, among others, including University of Oxford, University of California, Los Angeles (UCLA), and Harvard University. The project involved DNA sequencing and genotyping of DNA samples from population genetics studies, such as those conducted by University of Chicago and Stanford University.

Introduction

The International HapMap Project was launched in 2002, with the goal of creating a comprehensive map of human genetic variation, building on the work of Human Genome Project and Celera Genomics. The project involved a consortium of researchers from United States, United Kingdom, Canada, China, Japan, and Nigeria, including Broad Institute, Sanger Institute, and National Center for Biotechnology Information (NCBI). The project's steering committee included prominent researchers such as Eric Lander, Aravinda Chakravarti, and Charles Rotimi. The project's advisory board consisted of experts from World Health Organization (WHO), National Academy of Sciences (NAS), and European Molecular Biology Organization (EMBO).

Background and Goals

The International HapMap Project was motivated by the need to understand the genetic basis of complex diseases, such as diabetes, heart disease, and cancer, which are influenced by multiple genetic variants, as studied by National Cancer Institute (NCI) and American Heart Association (AHA). The project's primary goal was to identify common single nucleotide polymorphisms (SNPs) and haplotypes that are associated with these diseases, using statistical genetics and bioinformatics tools developed by University of Washington and Massachusetts Institute of Technology (MIT). The project also aimed to provide a resource for genetic association studies, which are used to identify genetic variants associated with disease, as conducted by National Institute of Environmental Health Sciences (NIEHS) and Centers for Disease Control and Prevention (CDC).

Methodology and Design

The International HapMap Project used a case-control study design, where DNA samples were collected from healthy individuals and patients with specific diseases, such as those studied by National Institute of Neurological Disorders and Stroke (NINDS) and National Institute of Mental Health (NIMH). The project used microarray technology and next-generation sequencing to genotype and sequence the DNA samples, as developed by Illumina and Life Technologies. The project also used bioinformatics tools and statistical methods to analyze the data, such as those developed by University of California, Berkeley and Columbia University. The project's data analysis was performed by researchers from University of Michigan and Duke University.

Data and Results

The International HapMap Project generated a vast amount of data, including genotype data and haplotype data, which are publicly available through NCBI and European Bioinformatics Institute (EMBL-EBI). The project identified millions of common SNPs and haplotypes, which are associated with various diseases, such as those studied by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The project's results have been published in numerous scientific papers, including those in Nature, Science, and New England Journal of Medicine, and have been cited by researchers from University of Cambridge and University of California, San Francisco (UCSF).

Impact and Applications

The International HapMap Project has had a significant impact on the field of genetics and genomics, as recognized by American Society of Human Genetics (ASHG) and International Society of Genetic Genealogy (ISOGG). The project's data and results have been used to identify genetic variants associated with various diseases, such as breast cancer and prostate cancer, as studied by National Breast Cancer Coalition (NBCC) and Prostate Cancer Foundation (PCF). The project has also led to the development of new genetic tests and therapies, such as those developed by Genentech and Biogen Idec. The project's results have been used by researchers from University of Pennsylvania and Johns Hopkins University to develop new treatments for diseases.

Criticisms and Controversies

The International HapMap Project has faced several criticisms and controversies, including concerns about informed consent and genetic privacy, as raised by American Civil Liberties Union (ACLU) and Genetic Alliance. Some critics have argued that the project's sampling strategy was biased towards European populations, as noted by National Institute on Minority Health and Health Disparities (NIMHD) and Office of Minority Health (OMH). Others have raised concerns about the project's data sharing policies and the potential for genetic discrimination, as discussed by National Human Genome Research Institute (NHGRI) and Presidential Commission for the Study of Bioethical Issues (PCSBI). Despite these criticisms, the project has been widely recognized as a major achievement in the field of genomics, as acknowledged by National Academy of Engineering (NAE) and Institute of Medicine (IOM). Category:Genomics projects